• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于对数秩检验和逐点检验统计量的自适应分组序贯生存比较。

Adaptive group sequential survival comparisons based on log-rank and pointwise test statistics.

机构信息

352489Institute of Biostatistics and Clinical Research, 9185University of Münster, Muenster, Germany.

出版信息

Stat Methods Med Res. 2021 Dec;30(12):2562-2581. doi: 10.1177/09622802211043262. Epub 2021 Oct 12.

DOI:10.1177/09622802211043262
PMID:34641702
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8649467/
Abstract

Whereas the theory of confirmatory adaptive designs is well understood for uncensored data, implementation of adaptive designs in the context of survival trials remains challenging. Commonly used adaptive survival tests are based on the independent increments structure of the log-rank statistic. This implies some relevant limitations: On the one hand, essentially only the interim log-rank statistic may be used for design modifications (such as data-dependent sample size recalculation). Furthermore, the treatment arm allocation ratio in these classical methods is assumed to be constant throughout the trial period. Here, we propose an extension of the independent increments approach to adaptive survival tests that addresses some of these limitations. We present a confirmatory adaptive two-sample log-rank test that allows rejection regions and sample size recalculation rules to be based not only on the interim log-rank statistic, but also on point-wise survival rate estimates, simultaneously. In addition, the possibility is opened to adapt the treatment arm allocation ratio after each interim analysis in a data-dependent way. The ability to include point-wise survival rate estimators in the rejection region of a test for comparing survival curves might be attractive, e.g., for seamless phase II/III designs. Data-dependent adaptation of the allocation ratio could be helpful in multi-arm trials in order to successively steer recruitment into the study arms with the greatest chances of success. The methodology is motivated by the LOGGIC Europe Trial from pediatric oncology. Distributional properties are derived using martingale techniques in the large sample limit. Small sample properties are studied by simulation.

摘要

虽然确证性适应性设计的理论对于未删失数据已经得到很好的理解,但在生存试验的背景下实施适应性设计仍然具有挑战性。常用的适应性生存检验基于对数秩统计量的独立增量结构。这意味着存在一些相关的局限性:一方面,基本上只能使用中期对数秩统计量来进行设计修改(例如,基于数据的样本量重新计算)。此外,这些经典方法中的处理臂分配比在整个试验期间被假定为常数。在这里,我们提出了一种对适应性生存检验的独立增量方法的扩展,该方法解决了其中的一些局限性。我们提出了一种确证性适应性两样本对数秩检验,允许拒绝区域和样本量重新计算规则不仅基于中期对数秩统计量,而且同时基于逐点生存率估计。此外,还可以在每次中期分析后以数据依赖的方式自适应地调整处理臂分配比。在比较生存曲线的检验中,将逐点生存率估计值纳入拒绝区域的能力可能具有吸引力,例如,用于无缝的 II/III 期设计。在多臂试验中,分配比的自适应可以帮助将招募逐步引导到成功率最高的研究臂。该方法学的动机来自儿科肿瘤学的 LOGGIC Europe 试验。在大样本极限下,使用鞅技术推导分布性质。通过模拟研究小样本性质。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/205e/8649467/96754e28a3bc/10.1177_09622802211043262-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/205e/8649467/3acf8a18629a/10.1177_09622802211043262-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/205e/8649467/96754e28a3bc/10.1177_09622802211043262-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/205e/8649467/3acf8a18629a/10.1177_09622802211043262-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/205e/8649467/96754e28a3bc/10.1177_09622802211043262-fig2.jpg

相似文献

1
Adaptive group sequential survival comparisons based on log-rank and pointwise test statistics.基于对数秩检验和逐点检验统计量的自适应分组序贯生存比较。
Stat Methods Med Res. 2021 Dec;30(12):2562-2581. doi: 10.1177/09622802211043262. Epub 2021 Oct 12.
2
Adaptive designs for the one-sample log-rank test.单样本对数秩检验的适应性设计。
Biometrics. 2018 Jun;74(2):529-537. doi: 10.1111/biom.12776. Epub 2017 Sep 22.
3
Confirmatory adaptive group sequential designs for single-arm phase II studies with multiple time-to-event endpoints.具有多个事件发生时间终点的单臂II期研究的验证性适应性成组序贯设计。
Biom J. 2022 Feb;64(2):312-342. doi: 10.1002/bimj.202000205. Epub 2021 Jul 16.
4
A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.用于生存结局临床试验的贝叶斯混合自适应随机化设计
Methods Inf Med. 2016;55(1):4-13. doi: 10.3414/ME14-01-0132. Epub 2015 Sep 25.
5
A group sequential, response-adaptive design for randomized clinical trials.一种用于随机临床试验的序贯群组、反应自适应设计。
Control Clin Trials. 2003 Oct;24(5):506-22. doi: 10.1016/s0197-2456(03)00092-8.
6
Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects.具有延迟效应的验证性研究设计中加权对数秩检验的性质
Pharm Stat. 2019 May;18(3):287-303. doi: 10.1002/pst.1923. Epub 2018 Dec 27.
7
Smoothing Corrections for Improving Sample Size Recalculation Rules in Adaptive Group Sequential Study Designs.平滑校正改进适应性分组序贯研究设计中的样本量重估规则。
Methods Inf Med. 2021 May;60(1-02):1-8. doi: 10.1055/s-0040-1721727. Epub 2021 Mar 1.
8
Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.具有离散检验统计量和超量考虑的适应性设计
Methods Inf Med. 2015;54(5):434-46. doi: 10.3414/ME14-02-0023. Epub 2015 Oct 2.
9
Sample size recalculation in three-stage clinical trials and its evaluation.三阶段临床试验中的样本量重估及其评价。
BMC Med Res Methodol. 2024 Sep 25;24(1):214. doi: 10.1186/s12874-024-02337-9.
10
Improving sample size recalculation in adaptive clinical trials by resampling.通过重采样改进自适应临床试验中的样本量重新计算。
Pharm Stat. 2021 Nov;20(6):1035-1050. doi: 10.1002/pst.2122. Epub 2021 Apr 1.

引用本文的文献

1
Identification and development of TP53 mutation-associated Long non-coding RNAs signature for optimized prognosis assessment and treatment selection in hepatocellular carcinoma.鉴定和开发与 TP53 突变相关的长非编码 RNA 标志物,用于优化肝细胞癌的预后评估和治疗选择。
Int J Immunopathol Pharmacol. 2023 Jan-Dec;37:3946320231211795. doi: 10.1177/03946320231211795.
2
CD163 as a Potential Biomarker in Colorectal Cancer for Tumor Microenvironment and Cancer Prognosis: A Swedish Study from Tissue Microarrays to Big Data Analyses.CD163作为结直肠癌中肿瘤微环境和癌症预后的潜在生物标志物:一项从组织微阵列到大数据分析的瑞典研究
Cancers (Basel). 2022 Dec 14;14(24):6166. doi: 10.3390/cancers14246166.

本文引用的文献

1
Sequential tests for non-proportional hazards data.非比例风险数据的序贯检验。
Lifetime Data Anal. 2017 Jul;23(3):339-352. doi: 10.1007/s10985-016-9360-5. Epub 2016 Mar 11.
2
Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials.适应性生存试验中的样本量重新评估与假设检验
PLoS One. 2016 Feb 10;11(2):e0146465. doi: 10.1371/journal.pone.0146465. eCollection 2016.
3
An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.一种用于肿瘤学试验的适应性无缝II/III期设计,该设计使用相关生存终点进行亚组选择。
Pharm Stat. 2011 Jul-Aug;10(4):347-56. doi: 10.1002/pst.472. Epub 2010 Dec 8.
4
Planning and analyzing adaptive group sequential survival trials.规划与分析适应性成组序贯生存试验
Biom J. 2006 Aug;48(4):714-29. doi: 10.1002/bimj.200510190.
5
Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections, by H. Schäfer and H.-H. Müller, Statistics in Medicine 2001; 20: 3741-3751.基于数据检查对生存试验中样本量和期中分析计划的调整,作者H. 舍费尔和H.-H. 米勒,《医学统计学》2001年;第20卷:3741 - 3751页
Stat Med. 2004 Apr 30;23(8):1333-4; author reply 1334-5. doi: 10.1002/sim.1759.
6
Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections.基于数据检查对生存试验中的样本量和期中分析计划进行调整。
Stat Med. 2001 Dec 30;20(24):3741-51. doi: 10.1002/sim.1136.